Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients.

Regueiro C, Ortiz AM, Boveda MD, Castañeda S, Gonzalez-Alvaro I, Gonzalez A.

PLoS One. 2018 Aug 17;13(8):e0202583. doi: 10.1371/journal.pone.0202583. eCollection 2018.

2.

Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.

Cañamares-Orbis I, Merino L, López J, Llorente I, García-Vadillo A, Ramirez E, López-Bote JP, Benedí J, Muñoz-Calleja C, Álvaro-Gracia JM, Castañeda S, González-Álvaro I.

J Clin Rheumatol. 2018 Jul 19. doi: 10.1097/RHU.0000000000000845. [Epub ahead of print]

3.

Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus.

González-Serna D, Ortiz-Fernández L, Vargas S, García A, Raya E, Fernández-Gutierrez B, López-Longo FJ, Balsa A, González-Álvaro I, Narvaez J, Gómez-Vaquero C, Sabio JM, García-Portales R, González-Escribano MF, Tolosa C, Carreira P, Kiemeney L, Coenen MJH, Witte T, Schneider M, González-Gay MÁ, Martín J.

Sci Rep. 2018 May 29;8(1):8195. doi: 10.1038/s41598-018-26573-4.

4.

Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.

López-Rodríguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A, Świerkot J, Slezak R, Dolžan V, González-Álvaro I, Narváez J, Cáliz R, Pérez-Pampín E, Mera-Varela A, Vidal-Bralo L, Acuña Ochoa JG, Conde C, Gómez-Reino JJ, González A.

Sci Rep. 2018 May 9;8(1):7342. doi: 10.1038/s41598-018-25634-y.

5.

Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.

López-Rodríguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A, Świerkot J, Slezak R, Gonzalez-Alvaro I, Narvaez J, Pérez-Pampín E, Mera-Varela A, Vidal-Bralo L, Acuña-Ochoa JG, Conde C, Gonzalez A.

Pharmacogenomics J. 2018 Jul;18(4):539-545. doi: 10.1038/s41397-018-0017-5. Epub 2018 Mar 8.

PMID:
29520081
6.

Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.

Municio C, Dominguez-Soto Á, Fuentelsaz-Romero S, Lamana A, Montes N, Cuevas VD, Campos RG, Pablos JL, González-Álvaro I, Puig-Kröger A.

Ann Rheum Dis. 2018 May;77(5):752-759. doi: 10.1136/annrheumdis-2017-212537. Epub 2018 Feb 3.

7.

Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.

Seoane IV, Martínez C, García-Vicuña R, Ortiz AM, Juarranz Y, Talayero VC, González-Álvaro I, Gomariz RP, Lamana A.

Sci Rep. 2018 Feb 1;8(1):2035. doi: 10.1038/s41598-018-20400-6.

8.

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.

González-Álvaro I, Blasco AJ, Lázaro P, Sánchez-Piedra C, Almodovar R, Bachiller-Corral J, Balsa A, Caliz R, Candelas G, Fernández-Carballido C, García-Aparicio A, García-Magallón B, García-Vicuña R, Gómez-Centeno A, Ortiz AM, Sanmartí R, Sanz J, Tejera B.

Heliyon. 2017 Nov 14;3(11):e00452. doi: 10.1016/j.heliyon.2017.e00452. eCollection 2017 Nov.

9.

Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study.

Toledano E, Ortiz AM, Ivorra-Cortes J, Montes N, Beltran A, Rodríguez-Rodriguez L, Carmona L, González-Álvaro I.

Clin Exp Rheumatol. 2018 May-Jun;36(3):382-388. Epub 2017 Nov 28.

PMID:
29185958
10.

[Medullar thoracic compression by tophaceous gout: presentation of a case and review of the literature].

Arevalo-Saenz A, Gonzalez-Alvaro I, Pulido-Rivas P, Vicente E, Garcia E, Castaneda S, Ocon E, Gomez-Leon N, Sola RG.

Rev Neurol. 2017 Oct 16;65(8):368-372. Spanish.

11.

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.

Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, González A.

Sci Rep. 2017 Sep 20;7(1):12023. doi: 10.1038/s41598-017-09657-5.

12.

Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach.

Lezcano-Valverde JM, Salazar F, León L, Toledano E, Jover JA, Fernandez-Gutierrez B, Soudah E, González-Álvaro I, Abasolo L, Rodriguez-Rodriguez L.

Sci Rep. 2017 Aug 31;7(1):10189. doi: 10.1038/s41598-017-10558-w.

13.

Severity indices in rheumatoid arthritis: A systematic review.

Toledano E, García de Yébenes MJ, González-Álvaro I, Carmona L.

Reumatol Clin. 2017 Aug 11. pii: S1699-258X(17)30180-8. doi: 10.1016/j.reuma.2017.07.004. [Epub ahead of print] English, Spanish.

15.

Novelties in the therapeutic scene of rheumatoid arthritis.

Castañeda S, González-Álvaro I.

Reumatol Clin. 2017 Mar - Apr;13(2):63-65. doi: 10.1016/j.reuma.2017.02.001. English, Spanish. No abstract available.

16.

mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis.

Castro-Sánchez P, Ramirez-Munoz R, Lamana A, Ortiz A, González-Álvaro I, Roda-Navarro P.

Clin Exp Immunol. 2017 Jul;189(1):113-119. doi: 10.1111/cei.12953. Epub 2017 Mar 28. Erratum in: Clin Exp Immunol. 2018 Feb;191(2):252.

17.

Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients.

Llorente I, Merino L, Ortiz AM, Escolano E, González-Ortega S, García-Vicuña R, García-Vadillo JA, Castañeda S, González-Álvaro I.

Rheumatol Int. 2017 May;37(5):799-806. doi: 10.1007/s00296-017-3674-9. Epub 2017 Feb 27.

18.

Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis.

López-Mejías R, Corrales A, Vicente E, Robustillo-Villarino M, González-Juanatey C, Llorca J, Genre F, Remuzgo-Martínez S, Dierssen-Sotos T, Miranda-Filloy JA, Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Ferraz-Amaro I, Gómez-Vaquero C, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I, Ocejo-Vinyals JG, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2017 Jan 6;7:40303. doi: 10.1038/srep40303.

19.

Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity.

Sala-Icardo L, Lamana A, Ortiz AM, García Lorenzo E, Moreno Fresneda P, García-Vicuña R, González-Álvaro I.

Reumatol Clin. 2017 Nov - Dec;13(6):318-325. doi: 10.1016/j.reuma.2016.08.006. Epub 2016 Oct 15. English, Spanish.

20.

Influence of patient personality in the treatment of rheumatoid arthritis.

Leon L, Redondo M, Garcia-Vadillo A, Perez-Nieto MA, Rodriguez-Rodriguez L, Jover JA, Gonzalez-Alvaro I, Abasolo L.

Rheumatol Int. 2016 Nov;36(11):1549-1555. Epub 2016 Sep 10.

PMID:
27614619

Supplemental Content

Loading ...
Support Center